![]()
|
|
||||||||
J. Biol. Chem., Vol. 277, Issue 16, 13804-13811, April 19, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
,From the Gene Regulation Program, Burnham Institute, La Jolla, California 92037
Received for publication, December 18, 2001, and in revised form, February 7, 2002
| |
ABSTRACT |
|---|
|
|
|---|
The ability of class I alcohol dehydrogenase
(ADH1) and class IV alcohol dehydrogenase (ADH4) to metabolize retinol
to retinoic acid is supported by genetic studies in mice carrying
Adh1 or Adh4 gene disruptions. To differentiate
the physiological roles of ADH1 and ADH4 in retinoid metabolism we
report here the generation of an Adh1/4 double null mutant
mouse and its comparison to single null mutants. We demonstrate that
loss of both ADH1 and ADH4 does not have additive effects, either for
production of retinoic acid needed for development or for retinol
turnover to minimize toxicity. During gestational vitamin A deficiency
Adh4 and Adh1/4 mutants exhibit completely
penetrant postnatal lethality by day 15 and day 24, respectively, while
60% of Adh1 mutants survive to adulthood similar to
wild-type. Following administration of a 50-mg/kg dose of retinol to
examine retinol turnover, Adh1 and Adh1/4
mutants exhibit similar 10-fold decreases in retinoic acid production, whereas Adh4 mutants have only a slight decrease.
LD50 studies indicate a large increase in acute retinol
toxicity for Adh1 mutants, a small increase for
Adh4 mutants, and an intermediate increase for
Adh1/4 mutants. Chronic retinol supplementation during
gestation resulted in 65% postnatal lethality in Adh1
mutants, whereas only ~5% for Adh1/4 and
Adh4 mutants. These studies indicate that ADH1 provides
considerable protection against vitamin A toxicity, whereas ADH4
promotes survival during vitamin A deficiency, thus demonstrating largely non-overlapping functions for these enzymes in retinoid metabolism.
One aspect of retinoid signaling that is not yet well understood
is the nature of the enzymes that metabolize vitamin A (retinol) to
retinoic acid (RA)1 either
for retinoid turnover or for production of the active form needed for
growth and development. Such metabolism is dependent upon enzymes
capable of catalyzing a two-step conversion of retinol to RA with
retinal as the intermediate (1). RA produced in this fashion either
functions as a ligand for RA receptors known to control vertebrate
development (2), or it is further metabolized to more polar derivatives
to facilitate excretion (3).
Studies on the second step of RA synthesis, oxidation of retinal to RA,
have yielded consistent results indicating that three forms of
cytosolic aldehyde dehydrogenase referred to as retinaldehyde dehydrogenase (RALDH) participate in RA synthesis (1). In
vitro activities are reported for RALDH1 (4), RALDH2 (5-7), and RALDH3 (8), plus in vivo activities are reported for RALDH1 and RALDH2 (9, 10). Gene disruption studies demonstrate that RALDH2 is
essential for catalyzing the second step of RA synthesis during
development as Raldh2 Several enzymes capable of catalyzing the first step of RA synthesis,
oxidation of retinol to retinal, have been identified within the
alcohol dehydrogenase (ADH) and short-chain dehydrogenase/reductase (SDR) families (1), plus there exists a recently identified cytosolic
form that is a member of the aldo-keto reductase family (13). The human
and mouse ADH families each contain five classes of cytosolic enzymes
(14) encoded by a tight cluster of genes tandemly organized in the same
transcriptional orientation on chromosome 4 (human) or chromosome 3 (mouse) (15). ADHs of class I (ADH1), class II (ADH2), and class IV
(ADH4) have long been known to catalyze the oxidation of retinol to
retinal in vitro (16-19), and recently class III (ADH3) has
been added to this list (20). The SDR family (21) includes the
microsomal enzymes RoDH (22), CRAD (23), and RDH5 (24) that can also
oxidize retinol to retinal in vitro. RDH5 functions in
vivo as an 11-cis-retinol dehydrogenase to generate the
visual pigment 11-cis-retinal (25, 26). Thus, microsomal
oxidation of retinol to retinal by SDRs may have functions distinct
from RA synthesis such as the one revealed for vision, whereas
cytosolic oxidation of retinol to retinal by ADH or aldo-keto reductase
may contribute to RA synthesis by cytosolic RALDHs.
Gene disruption studies have also provided evidence of a physiological
function for ADH in RA production. Adh4 To examine the physiological roles of ADH1 and ADH4 in retinoid
metabolism we report here the generation of an Adh1/4 double null mutant mouse line and its comparison to single null mutants when
challenged by vitamin A deficiency or toxicity. These genetic findings
demonstrate that ADH1 and ADH4 have evolved to perform largely
non-overlapping roles in retinoid metabolism, ADH1 in minimizing
vitamin A toxicity and ADH4 in survival during VAD.
Construction of Adh1-hygro Gene Targeting Vector--
A gene
replacement targeting vector for Adh1 carrying a
hygromycin-positive selection marker (PGK-hygro) was
produced by alteration of an Adh1 targeting vector
containing a neomycin-positive selection marker (PGK-neo) as
well as a thymidine kinase-negative selection marker
(PGK-TK) as previously described (28). A portion of the neomycin resistance gene was removed from this vector with
BamHI and XhoI and replaced with a 2.2-kb
BamHI-XhoI fragment containing the hygromycin
resistance gene controlled by the PGK promoter (33). In this
vector, exons 7-9 plus the polyadenylation signal of Adh1
are replaced by PGK-hygro.
Generation of Adh1/4 Double Null Mutant Mice--
The
Adh1-hygro gene targeting vector described above was
linearized with NotI and introduced by electroporation using
standard methodology (34) into Adh4+/
Several Adh1+/ Generation of VAD Mice--
Gestational VAD was induced by a
modification of previous methods (27). For each mouse strain, original
parental mice (three mating pairs each) were placed on Purina VAD diet
5822 (vitamin A <0.22 IU/g) at the beginning of mating, and resulting
offspring were maintained on this diet. Congenitally VAD F1
generation females were mated at 6-weeks-old (to males maintained on
standard mouse chow to remain fertile), thus producing congenitally VAD
F2 generation offspring. For both rounds of matings,
females were separated from males before birth to ensure that they did
not again become pregnant during postnatal development of their
offspring. Blood was collected and serum all-trans-retinol
was quantitated by HPLC analysis as indicated below.
Acute Retinol Treatment--
For analysis of retinoic acid
production following a single acute retinol dose, retinol was
administered essentially as described (38).
All-trans-retinol (Sigma) was dissolved in acetone-Tween 20-water (0.25:5:4.75 v/v/v) and was administered at a dose of 50 mg/kg
by oral injection to female mice (age- and weight-matched). After
2 h, liver and blood were collected and stored at
For determination of the retinol lethal dose, mice were given a single
oral dose of retinol as previously reported (29). Male 14-week-old mice
were used for all strains examined. All-trans-retinol (Sigma) was dissolved in corn oil and administered by oral intubation at 0.2 ml/10 g of body weight. Doses ranged from 0.5 to 3.5 g/kg. Lethality was monitored daily during 14 days after retinol
administration. A dose resulting in the death of 50% of the mice
(LD50) by day 14, plus the 95% confidence limits for the
LD50 dose, were calculated using the methods of Litchfield
and Wilcoxon (39).
HPLC Measurement of Retinol and Retinoic Acid--
Liver (250 mg) was homogenized on ice in 2 ml of methanol-acetone (50:50 v/v),
whereas serum (200 µl) was extracted with 2 ml of methanol-acetone
(50:50 v/v). After centrifugation at 10,000 × g for 10 min at 4 °C, the organic phase was evaporated under vacuum, and the
residue was dissolved in 200 µl of methanol-dimethyl sulfoxide (50:50
v/v). Samples were analyzed by HPLC to quantitate retinoid levels using
standards for all-trans-RA and all-trans-retinol (Sigma). Reversed-phase HPLC analysis was performed using a
Microsorb-MVTM 100 C18 column (4.5 × 250 mm) (Varian) at a flow
rate of 1 ml/min. Mobile phase consisted of 0.5 M ammonium
acetate-methanol-acetonitrile (25:65:10 v/v) (solvent A) and
acetonitrile (solvent B). The A:B (v/v) gradient composition was 100:0
at the time of injection, 70:30 at 1 min, 65:35 at 14 min, and 0:100 at
16 min. UV detection was carried out at 340 nm.
Dietary Vitamin A Supplementation--
Statistical
significance was determined for raw data with Statistica version 5.0 software using the unpaired Student's t test (two-tailed).
Mice were propagated on either Purina 5015 standard mouse chow,
which contains the standard amount of vitamin A (30 IU/g) or Purina
5755 basal diet supplemented with additional retinyl acetate to bring
the total vitamin A concentration to 300 IU/g all in the form of
retinyl acetate, which is quickly hydrolyzed to retinol in the
digestive tract. Two groups of adult female mice, which had been
placed on one or the other of these diets for 2 weeks, were mated with
males while being maintained on their respective diets to generate
offspring, which were also maintained, respectively, on the same diet
after weaning.
Generation of Adh1/4 Double Null Mutant Mice--
Mice
carrying single null mutants for either Adh1 or
Adh4 have been previously described (27, 28). Analysis of
the mouse Adh gene complex (15) has shown that
Adh1 and Adh4 are closely linked on mouse
chromosome 3 along with four other functional Adh genes and
a pseudogene (Fig. 1B). Thus,
a double null mutant would not be able to be obtained by simple matings
of the two single mutants unless a rare crossing-over event occurred
between the two mutant genes on homologous chromosomes to produce a
single copy of chromosome 3 carrying both mutations. Instead, double null mutants were obtained by sequential gene targeting of ES cells
starting with Adh4+/
Mating of Adh1/4+/ Survival and Growth of Adh Null Mutant Mice--
To determine
whether the loss of ADH1 or ADH4 or both enzymes negatively impacts
viability and growth when maintained under normal laboratory
conditions, we examined the generation, survival, and growth of each of
the mouse strains on standard mouse chow. Adh1 Effect of VAD on Adh Null Mutant Mice--
We previously reported
that Adh4
Adh4
Measurement of serum retinol in the female mice used to generate the
VAD F2 generation offspring verified that each mouse strain
had become essentially equally deficient (Fig.
3). Values for serum
all-trans-retinol in control females maintained on standard mouse chow ranged from 0.3-0.4 µg/ml among the strains, and this fell to 0.1-0.17 µg/ml for the original female parents maintained on
the VAD diet for 8 weeks and fell further to ~0.03 µg/ml for each
strain of congenitally VAD F1 generation females that
served as parents for the F2 generation described above.
Thus, the completely penetrant postnatal lethality observed in
Adh4
As Adh1 Effect of Adh Genotype on Metabolism of Retinol to Retinoic
Acid--
To examine oxidative turnover of retinol, mice were treated
orally with a 50-mg/kg dose of all-trans-retinol, and 2 h later all-trans-RA was quantitated in liver and serum. WT
mice generated high levels of all-trans-RA in response to
this dose of retinol (2.0 ± 0.6 µg/ml in liver and 1.4 ± 0.5 µg/ml in serum). We observed that
Adh1 Determination of Retinol LD50 Values to Examine Acute
Retinol Toxicity--
We examined the effect of Adh
genotype on acute retinol toxicity by determining the LD50
values for each null mutant strain compared with WT. In our hands, WT
mice exhibited a retinol LD50 value of 2.72 g/kg, very
close to the value of 2.52 g/kg previously reported for mice (29).
Retinol toxicity was greatly increased in
Adh1 Chronic Retinol Toxicity via Dietary Retinol
Supplementation--
To examine the effect of chronic retinol
treatment on development, mice were propagated for one generation on a
retinol-supplemented diet (300 IU/g) containing 10-fold higher vitamin
A than normal mouse chow (30 IU/g). Adh1 The findings reported here indicate that ADH1 and ADH4 have mostly
non-overlapping functions in retinol metabolism in vivo. This conclusion was achieved by comparison of
Adh1/4 ADH4, but not ADH1, provides protection against gestational VAD as
100% postnatal lethality is observed in
Adh4 Examination of oxidative retinol turnover provided clear evidence that
ADH1 plays a major role in this metabolic pathway, with ADH4 playing a
relatively minor role. Adh1 Consistent with the retinol metabolic studies, we show that ADH1, but
not ADH4, provides a great deal of protection against acute retinol
toxicity in adult mice and chronic retinol toxicity during gestation.
The LD50 values show that
Adh1/4 The observation that ADH1 and ADH4 do not have additive effects on
retinoid metabolism during VAD or vitamin A toxicity can also be
coupled with the observation that they do not have additive effects
during development, i.e. Adh1/4
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
/
embryos die at
mid-gestation and almost totally lack RA (11, 12).
Raldh2
/
embryonic development can be
partially rescued with limited maternal RA treatment, and rescued
embryos express RALDH1 and RALDH3 as well as at least one additional
RA-generating enzyme, all of which may contribute to the rescue
(12).
/
mice are viable but suffer increased postnatal lethality during gestational vitamin A deficiency (VAD) compared with wild-type mice
(27). Thus, ADH4 can be considered essential for RA production to
ensure postnatal survival during VAD, a condition commonly encountered
by animals in natural environments. Studies on
Adh3
/
mice have shown that ADH3 also
minimizes the effect of gestational VAD but is also needed to maintain
growth on a standard diet (20). In addition,
Adh1
/
mice are viable and behave no worse
than wild-type mice during gestational VAD (20) but suffer a large
reduction in metabolism of a dose of retinol to RA (28). Thus, whereas
ADH3- and ADH4-catalyzed RA production is necessary for supplying the
ligand for nuclear receptors to fulfill the function of vitamin A in
development, it is possible that ADH1-catalyzed RA synthesis functions
in another fashion, perhaps the oxidative elimination of excess retinol
to prevent vitamin A toxicity. That excess vitamin A is toxic has been
well established (29-31) and has resulted in the recommendation that
consumption of vitamin A-rich foods or vitamin A supplements be
limited, particularly during pregnancy as fetal development is most
sensitive (32). The main oxidative pathway for retinol turnover is the
oxidation of retinol to retinal and then oxidation of retinal to RA
followed by glucuronide conjugation of the acid and/or 4-hydroxylation
of RA (3). The enzyme responsible for oxidizing excess retinol to
retinal to initiate this catabolic pathway has not been identified.
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
mouse
embryonic stem (ES) cells that were previously targeted for
Adh4 with a neomycin resistance marker (27). To
enrich for Adh4+/
ES cells incorporating the
Adh1-hygro construct by homologous recombination, positive
selection was with 125 µg/ml hygromycin B and negative selection was
with 2 µM gancyclovir. Identification of
Adh4+/
ES cells carrying also a deletion in
Adh1 was accomplished by Southern blot analysis of genomic
DNA isolated from ~200 surviving cell clones (35). Genomic DNA was
digested with HindIII, and an external DNA probe for
Southern blot analysis consisted of a 0.2-kb
EcoRV-HindIII fragment from the 3'-flanking
region of Adh1 (36). The wild-type and mutant
Adh1 alleles were identified by 2.8- and 5.7-kb
HindIII fragments, respectively. As it was desired to obtain
an ES cell clone in which the Adh1 targeting event had
occurred on the same copy of chromosome 3 already targeted for
Adh4 as opposed to the wild-type chromosome 3, several
independently isolated double-targeted clones were isolated.
Adh4+/
double heterozygous ES cell clones were subjected to karyotype analysis
to identify those having a normal karyotype for blastocyst injection.
Adh1+/
Adh4+/
ES cell
clones (clones 9 and 64) were microinjected into C57Bl/6 blastocysts,
which were then implanted into pseudopregnant females resulting in
chimeric mice identified by partial agouti coat color (34). Male
chimeric mice derived from each ES cell line were mated to wild-type
female Black Swiss mice, and germ line transmission was identified by
agouti coat color. Agouti offspring were subjected to Southern blot
analysis of tail DNA (35) to identify
Adh1+/
Adh4+/
individuals heterozygous for mutations in both Adh1 and
Adh4 using the probe described above for Adh1 as
well as an Adh4 probe described previously in which the
wild-type and mutant Adh4 alleles are identified by 4.0-kb
and 5.8-kb HindIII fragments, respectively (27). Mice
derived from ES cell clone 9 were found to possess mutations in both
Adh1 and Adh4 and hence carry a copy of
chromosome 3 in which both genes are mutated. Heterozygous
Adh1+/
Adh4+/
matings were performed to produce homozygous
Adh1
/
Adh4
/
mice and
wild-type mice identified by Southern blot analysis of tail DNA.
Adh1
/
Adh4
/
mice
(referred to as Adh1/4 null mutant mice or
Adh1/4
/
mice) and wild-type mice were then
expanded to form permanent mouse lines maintained under standard
laboratory conditions. Other mice used in this study are the original
Adh1
/
and Adh4
/
null mutant lines previously described (27, 28) both of which have the
same genetic background as the Adh1/4 and wild-type mice described here. For verification of a null mutant phenotype, polyclonal antibodies against mouse ADH1 and ADH4 were used to probe Western blots
of mouse liver and stomach using 20 µg of total protein per lane as
reported (37).
20 °C until
HPLC analysis as described below.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
ES cells, i.e.
the cell line used to generate Adh4
/
mice
targeted with an Adh4-neo vector providing G418 selection (27). As Adh4+/
ES cells already possess G418
resistance, they were electroporated with an Adh1-hygro gene
targeting vector that carries the hygromycin selectable marker (Fig.
1A). Incorporation of this vector deletes exons 7-9 plus
the polyadenylation site, thus producing the same type of mutation
previously reported for Adh1
/
mice that were
targeted with an Adh1-neo vector (28). As this gene
targeting event could occur either on the copy of chromosome 3 containing the null mutant allele of Adh4 (which was
desired) or on the other copy containing the wild-type allele of
Adh4 (not desired), this was sorted out when targeted ES
cells were introduced into mice and screened by Southern blot analysis
for mutations in both Adh1 and Adh4 as described
under "Experimental Procedures." One ES cell line (clone 9)
produced the desired result, thus generating Adh1+/
Adh4+/
(Adh1/4+/
) double heterozygous mice in which
the two mutant alleles segregated essentially as a single trait.

View larger version (24K):
[in a new window]
Fig. 1.
Targeting of both Adh1 and
Adh4 on the same chromosome. A, shown
are the wild-type Adh1 gene containing nine exons, the
Adh1-hygro gene replacement targeting vector, and the mutant
Adh1 locus in which exons 7-9 and the polyadenylation
signal have been deleted (replaced by the hygromycin resistance
gene PGK-hygro). B, a comparison of the ADH gene
complexes for mouse (chromosome 3) and human (chromosome 4) shows that
each species contains five classes of ADH genes (numbered 1-5)
arranged in the same order with arrows indicating that all
genes are in the same transcriptional orientation; mouse and human
differ in that mouse contains three class V genes (one being a
pseudogene indicated by cross-hatching), whereas human
contains three class I genes (15). For mouse, it can be seen that
Adh4 and Adh1 (shown here with an X
indicating the site of targeting with neomycin (neo) or
hygromycin (hygro)) are located close together at the
upstream end of the complex.
mice resulted in the
production of Adh1/4
/
double homozygous mice
that were viable and that were generated at the normal Mendelian ratio
(10 litters from double heterozygous parents resulted in
/
, 26%,
n = 21;
/+, 46%, n = 36; +/+, 28%, n = 22). This is similar to the results reported for
each single mutant (27, 28). Also, Adh1/4
/
mice were fertile and a homozygous line was established. Western blot
analysis verified that Adh1/4
/
mice lacked
both ADH1 and ADH4 proteins (data not shown).
/
, Adh4
/
, and
Adh1/4
/
mice showed no significant
difference with wild-type (WT) with respect to reproductive ability,
survival, or body weight at maturity (Table
I). As Adh1/4
/
mice were able to reproduce and develop similar to
Adh1
/
and
Adh4
/
single mutants, this indicates that a
third retinol-metabolizing enzyme must exist for production of RA
needed during development.
Survival and growth of mice lacking ADH1 or ADH4 or both
/
mice exposed to
gestational VAD suffer increased postnatal lethality compared with WT
mice (27). Here we compared Adh4
/
and WT
mice with Adh1
/
and
Adh1/4
/
mice for survival and
growth during gestational VAD. Mice were mated for two generations on a
VAD diet in order to induce severe deficiency in the F2
generation during development. As expected from previous studies (27),
Adh4
/
F2 generation mice were
severely effected by VAD, displaying 100% lethality by postnatal day
15 (P15) (Fig. 2, A and
B). In contrast, WT and Adh1
/
mice both exhibited ~60% survival at P40.
Adh1/4
/
mice did not perform worse than
Adh4
/
mice, but instead survived a little
longer, with 100% lethality by P24 (Fig. 2, A and
B)

View larger version (15K):
[in a new window]
Fig. 2.
Effect of Adh
gene targeting on postnatal lethality during gestational
VAD. A, shown are the number of congenitally VAD
F2 generation offspring born for
Adh1
/
, Adh4
/
,
Adh1/4
/
, and WT mice, and the number of
individuals that survived until P40. 100% postnatal lethality is
indicated for Adh4
/
and
Adh1/4
/
mice by P15 and P24, respectively.
B, the data in the previous panel are shown plotted as the
% survival for each mouse strain. C, shown are the weight
gains from birth to P40 for the VAD mice in the previous panels. *,
100% postnatal mortality occurred by the day indicated. Data for some
of the mice used here (WT, Adh1
/
, and
Adh4
/
) are also described previously
(20).
/
and Adh1/4
/
VAD mice exhibited severe growth deficiency in the F2
generation compared with WT and Adh1
/
mice.
Whereas WT and Adh1
/
mice had comparable
body weights from birth to P40 and achieved weights of 16-18 g, growth
of Adh4
/
mice began to deviate downward from
WT at P4, and body weights beyond 3 g were not achieved before
death; growth of Adh1/4
/
mice began to
deviate downward from WT at P8, and body weights beyond 6 g were
not achieved before death (Fig. 2C)
/
and Adh1/4
/
mice subjected to VAD was not due to significant differences in the
level of serum all-trans-retinol in these strains relative to WT and Adh1
/
mice.

View larger version (18K):
[in a new window]
Fig. 3.
Depletion of serum retinol during gestational
VAD. HPLC quantitation of serum all-trans-retinol
during VAD was performed for WT, Adh1
/
,
Adh4
/
, and
Adh1/4
/
female mice matched for age. On the
left, control values are shown for 14-week-old vitamin
A-sufficient female mice (n = 3) for each strain
maintained on standard mouse chow. In the middle, values for
VAD (original parents) refer to the original female parents used to
begin the VAD studies (n = 3), which were placed on the
VAD diet at 6-weeks-old, mated to produce one litter, and then examined
for serum retinol at 14-weeks-old. On the right, values for
VAD (F1 generation) refer to the female offspring
(n = 8) of the original VAD female parents; these
congenitally VAD offspring underwent a single mating at 6-weeks-old to
produce the F2 generation mice described in Fig. 2, and
then serum retinol was measured at 14-weeks-old. Serum retinol data are
also presented elsewhere for some of the strains (WT,
Adh1
/
, and Adh4
/
)
(20).
/
mice and WT had similar survival
and growth during VAD, there is no evidence that ADH1 provides
protection against VAD. Also, there is no additive effect on VAD when
both ADH1 and ADH4 are missing. Instead, these experiments show that
when mice lacking both ADH1 and ADH4 are exposed to VAD, they will
survive longer and experience more growth than mice lacking only ADH4. This interesting relationship between ADH1 and ADH4 is discussed further below.
/
mice had a 10-fold reduction of
all-trans-RA in liver (0.2 ± 0.02 µg/ml) and a
23-fold reduction in serum (0.06 ± 0.03 µg/ml) relative to WT
(Fig. 4).
Adh1/4
/
mice behaved similarly to
Adh1
/
mice, whereas
Adh4
/
mice had small decreases of
all-trans-RA in liver (1.5 ± 0.7 µg/ml) and serum
(1.3 ± 0.7 µg/ml) that were not statistically different from WT
(Fig. 4). These findings demonstrate a very large role for ADH1 in
oxidative clearance of retinol. ADH4 was found to contribute very
little to this metabolism, and Adh1/4
/
mice
did not exhibit a further reduction in RA production relative to
Adh1
/
mice.

View larger version (12K):
[in a new window]
Fig. 4.
Contribution of ADH1 and/or ADH4 to
metabolism of retinol to RA. All-trans-RA levels were
quantitated by HPLC in liver (µg/g) and serum (µg/ml) of WT,
Adh1
/
, Adh4
/
, and
Adh1/4
/
female mice 2 h after a
50-mg/kg oral dose of all-trans-retinol. All values are from
adult female mice (n = 4). Serum RA data for WT,
Adh1
/
, and Adh4
/
are also reported previously (20). All values are means ± S.E. *,
p < 0.01; **, p < 0.03; ***
p < 0.05 (significantly different from the WT value;
unpaired Student's t test).
/
mice, which exhibited a much smaller
LD50 of 0.9 g/kg (3-fold less than WT), whereas there was a
much smaller increase in toxicity in Adh4
/
mice (LD50 = 1.74 g/kg, 1.6-fold less than WT) but an
intermediate level of toxicity in Adh1/4
/
mice (LD50 = 1.22 g/kg, 2.2-fold less than WT) (Fig.
5). These findings indicate that ADH1
plays a major role in providing protection against retinol toxicity,
whereas ADH4 plays a relatively minor role. Importantly, the loss of
both does not lead to a further increase in toxicity. Instead, the
Adh1/4
/
results show that the greatly
increased retinol toxicity observed when ADH1 is missing is moderated
when ADH4 is also missing, further pointing out an interesting
relationship between ADH1 and ADH4.

View larger version (18K):
[in a new window]
Fig. 5.
Retinol toxicity assessed by retinol
LD50 determination. Retinol LD50 values
are compared for WT, Adh1
/
,
Adh4
/
, and
Adh1/4
/
mice. All values are means ± S.E. *, p < 0.05 (significantly different from the WT
value; Litchfield and Wilcoxon test).
/
mice exhibited a high incidence of postnatal mortality from birth through day 3 resulting in only 36% survival to adulthood compared with Adh4
/
and WT mice, which each exhibited
~95% survival to adulthood (Fig. 6,
A and B). Interestingly, the retinol-supplemented
diet did not have a noticeable effect on survival of
Adh1/4
/
mice, which behaved similar to WT
(Fig. 6, A and B). This moderate level of retinol
supplementation did not have a noticeable teratogenic effect on any
strains nor an effect on survival or growth of any mice that survived
past postnatal day 3 including those Adh1
/
mice that survived past that point (Fig. 6C). Thus,
excessive death of Adh1
/
mice shortly after
birth is most likely associated with a perturbation in the immediate
adjustments needed for life outside the womb such as respiration,
feeding, or digestive tract function. As the results for
Adh1/4
/
mice indicate, the additional loss
of ADH4 eliminates this toxic event. This provides yet one more example
of a situation where the negative effect resulting from loss of ADH1 is
moderated by the additional loss of ADH4.

View larger version (12K):
[in a new window]
Fig. 6.
Effect of Adh genotype on
postnatal lethality during chronic retinol treatment.
A, shown are the number of offspring born for
Adh1
/
, Adh4
/
,
Adh1/4
/
, and WT mice generated on a
retinol-supplemented diet (300 IU/g vitamin A) and the number of
individuals that survived until P40. B, the data in the previous panel
are shown plotted as the % survival for each mouse strain.
Adh1
/
mice experienced ~65% postnatal
mortality between birth and P3, whereas the other strains had similar
low levels of mortality (~5%). C, shown are the weight gains from
birth to P45 for the retinol-treated mice in the previous panels.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
/
double null mutant mice with
Adh1
/
and Adh4
/
single null mutant mice challenged with VAD or vitamin A toxicity. If
ADH1 and ADH4 each provided protection against retinol deficiency and
toxicity, we would have observed additive effects. However, this was
not observed, and instead we revealed conditions in which the effect of
a loss of one gene was moderated by the additional loss of the other gene.
/
mice under VAD conditions where
Adh1
/
and wild-type mice suffer only 40%
postnatal lethality and show similar growth as described previously
(20) and reported here for comparison with
Adh1/4
/
mice. Our results here demonstrate
that VAD Adh1/4
/
mice do not perform worse
than VAD Adh4
/
mice during gestation,
providing further evidence that ADH1 does not function to provide
protection against VAD. Instead, Adh1/4
/
offspring display more growth and survive longer than
Adh4
/
mice during VAD. As 100% postnatal
lethality is still observed in both strains, the effect of ADH4 is
dominant. However, the additional loss of ADH1 moderates the negative
effect of a loss of ADH4 during gestational VAD perhaps by reducing
retinol turnover.
/
mice exhibit a
10-fold decrease in metabolism of retinol to RA in liver. This
correlates with liver being the tissue where ADH1 protein is most
highly expressed in the adult mouse (37). In contrast,
Adh4
/
mice have a small decrease in
conversion of retinol to RA in liver that is not statistically
significant. In addition, Adh1/4
/
mice
behave similar to Adh1
/
mice, indicating
that there is not an additive effect when ADH1 and ADH4 retinol
activities are both eliminated. As mammalian ADH1 and ADH4 each have
high activity for oxidation of retinol to retinal (ADH1 activity
reported as 30-300 nmol/min/mg; ADH4 activity reported as 110-1675
nmol/min/mg) (16-19), the lack of a major contribution by ADH4
in vivo is not due to lower retinol activity. However, it is
consistent with the fact that ADH4 protein is not produced in mouse
liver where a large amount of retinol metabolism is expected to occur
(37). Adh1
/
and
Adh1/4
/
mice, but not
Adh4
/
mice, also exhibit large decreases in
serum RA after retinol treatment, indicating that tissues expressing
ADH1 are involved in most of the systemic turnover of retinol to RA,
some of which escapes to the blood before further metabolism. ADH4
protein is found in the epithelia of several retinoid target tissues
including the stomach, esophagus, skin, and respiratory tract (37, 40), but these tissues evidently do not account for much of the observed RA
in the serum. This is likely due to the relatively small number of
cells expressing ADH4 in those organs compared with the large number of
cells in the liver expressing ADH1 at very high levels; in the mouse,
0.9% of liver protein is ADH1, whereas only 0.07% of stomach protein
is ADH4 (41). Thus, the expression pattern of ADH4 precludes it from
playing a major role in systemic retinol turnover but evidently allows
it to function in metabolism of retinol to RA in peripheral tissues to
provide protection against VAD.
/
mice do not have greater retinol
toxicity than Adh1
/
mice, but rather an
intermediate level of toxicity between that of
Adh1
/
and Adh4
/
mice, indicating that there is not an additive effect on toxicity when
both ADH1 and ADH4 are missing but instead a moderating effect. Thus,
some of the observed toxicity in Adh1
/
mice
may be due to excessive retinol utilization by ADH4 in peripheral tissues, and this is eliminated in Adh1/4
/
mice. Additional toxicity may result if retinol is not efficiently oxidized though an ADH1 pathway and is instead used as a substrate by
P450s known to metabolize retinol to 4-hydroxyretinol (42). As
P450-mediated metabolism requires molecular oxygen and produces oxygen-free radicals that can cause liver damage (43, 44), this may
contribute to the increased incidence of death observed in our
LD50 studies of Adh1
/
mice. We conclude
that ADH1 minimizes toxicity by metabolizing retinol quickly to RA in
the liver, thus diminishing retinol utilization both by ADH4 in
peripheral tissues as well as by P450s in liver or elsewhere.
/
mice lacking both of these enzymes are viable and can reproduce when
maintained under normal laboratory conditions on a standard diet. Thus,
although ADH4 facilitates development during VAD, there exists at least
one additional retinol-oxidizing enzyme that functions physiologically
to produce retinal for RA production throughout development. The most
obvious candidate is ubiquitously expressed ADH3 for which there now
exists genetic evidence of a physiological function in RA synthesis and
growth (20).
| |
ACKNOWLEDGEMENTS |
|---|
We thank F. Mic for helpful discussions and the Burnham Institute Mouse Genetics Facility for animal maintenance.
| |
FOOTNOTES |
|---|
* This work was supported by National Institutes of Health Grant AA09731 (to G. D.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Present address: Institut Cochin de Genetique Moleculaire,
INSERM U257, 24 rue du Faubourg Saint Jacques, 75014 Paris, France.
§ Present address: Center National de Génotypage, 2 rue Gaston Crémieux, BP 191, 91006 Evry Cedex, France.
¶ To whom correspondence should be addressed: Gene Regulation Program, Burnham Institute, 10901 N. Torrey Pines Rd., La Jolla, CA 92037. Tel.: 858-646-3138; Fax: 858-646-3195; E-mail: duester@burnham.org.
Published, JBC Papers in Press, February 8, 2002, DOI 10.1074/jbc.M112039200
| |
ABBREVIATIONS |
|---|
The abbreviations used are: RA, retinoic acid; RALDH, retinaldehyde dehydrogenase; ADH, alcohol dehydrogenase; SDR, short-chain dehydrogenase/reductase; Adh, mouse alcohol dehydrogenase gene; VAD, vitamin A deficiency/vitamin A-deficient; ES, embryonic stem; HPLC, high pressure liquid chromatography, WT, wild-type; P, postnatal day.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Duester, G.
(2000)
Eur. J. Biochem.
267,
4315-4324[Medline]
[Order article via Infotrieve] |
| 2. |
Kastner, P.,
Mark, M.,
and Chambon, P.
(1995)
Cell
83,
859-869[CrossRef][Medline]
[Order article via Infotrieve] |
| 3. | Frolik, C. A. (1984) in The Retinoids (Sporn, M. B. , Roberts, A. B. , and Goodman, D. S., eds), Vol. 2 , pp. 177-208, Academic Press, Orlando, FL |
| 4. |
Labrecque, J.,
Dumas, F.,
Lacroix, A.,
and Bhat, P. V.
(1995)
Biochem. J.
305,
681-684 |
| 5. |
Zhao, D.,
McCaffery, P.,
Ivins, K. J.,
Neve, R. L.,
Hogan, P.,
Chin, W. W.,
and Dräger, U. C.
(1996)
Eur. J. Biochem.
240,
15-22[Medline]
[Order article via Infotrieve] |
| 6. |
Wang, X. S.,
Penzes, P.,
and Napoli, J. L.
(1996)
J. Biol. Chem.
271,
16288-16293 |
| 7. | Gagnon, I., Duester, G., and Bhat, P. V. (2002) Biochim. Biophys. Acta, in press |
| 8. |
Grün, F.,
Hirose, Y.,
Kawauchi, S.,
Ogura, T.,
and Umesono, K.
(2000)
J. Biol. Chem.
275,
41210-41218 |
| 9. |
Ang, H. L.,
and Duester, G.
(1999)
Eur. J. Biochem.
260,
227-234[Medline]
[Order article via Infotrieve] |
| 10. |
Haselbeck, R. J.,
Hoffmann, I.,
and Duester, G.
(1999)
Dev. Genet.
25,
353-364[CrossRef][Medline]
[Order article via Infotrieve] |
| 11. |
Niederreither, K.,
Subbarayan, V.,
Dollé, P.,
and Chambon, P.
(1999)
Nat. Genet.
21,
444-448[CrossRef][Medline]
[Order article via Infotrieve] |
| 12. | Mic, F. A., Haselbeck, R. J., Cuenca, A. E., and Duester, G. (2002) Development, in press |
| 13. |
Crosas, B.,
Cederlund, E.,
Torres, D.,
Jörnvall, H.,
Farrés, J.,
and Parés, X.
(2001)
J. Biol. Chem.
276,
19132-19140 |
| 14. |
Duester, G.,
Farrés, J.,
Felder, M. R.,
Holmes, R. S.,
Höög, J.-O.,
Parés, X.,
Plapp, B. V.,
Yin, S.-J.,
and Jörnvall, H.
(1999)
Biochem. Pharmacol.
58,
389-395[CrossRef][Medline]
[Order article via Infotrieve] |
| 15. |
Szalai, G.,
Duester, G.,
Friedman, R.,
Jia, H.,
Lin, S.,
Roe, B. A.,
and Felder, M. R.
(2002)
Eur. J. Biochem.
269,
224-232[Medline]
[Order article via Infotrieve] |
| 16. |
Boleda, M. D.,
Saubi, N.,
Farrés, J.,
and Parés, X.
(1993)
Arch. Biochem. Biophys.
307,
85-90[CrossRef][Medline]
[Order article via Infotrieve] |
| 17. |
Yang, Z.-N.,
Davis, G. J.,
Hurley, T. D.,
Stone, C. L., Li, T.-K.,
and Bosron, W. F.
(1994)
Alcohol. Clin. Exp. Res.
18,
587-591[CrossRef][Medline]
[Order article via Infotrieve] |
| 18. |
Han, C. L.,
Liao, C. S., Wu, C. W.,
Hwong, C. L.,
Lee, A. R.,
and Yin, S. J.
(1998)
Eur. J. Biochem.
254,
25-31[Medline]
[Order article via Infotrieve] |
| 19. |
Crosas, B.,
Allali-Hassani, A.,
Martínez, S. E.,
Martras, S.,
Persson, B.,
Jörnvall, H.,
Parés, X.,
and Farrés, J.
(2000)
J. Biol. Chem.
275,
25180-25187 |
| 20. | Molotkov, A., Fan, X., Deltour, L., Foglio, M. H., Martras, S., Farrés, J., Parés, X., and Duester, G. (2002) Proc. Natl. Acad. Sci. U. S. A., in press |
| 21. |
Jörnvall, H.,
Höög, J. O.,
and Persson, B.
(1999)
FEBS Lett.
445,
261-264[CrossRef][Medline]
[Order article via Infotrieve] |
| 22. |
Boerman, M. H. E. M.,
and Napoli, J. L.
(1995)
Arch. Biochem. Biophys.
321,
434-441[CrossRef][Medline]
[Order article via Infotrieve] |
| 23. |
Chai, X. Y.,
Zhai, Y.,
and Napoli, J. L.
(1997)
J. Biol. Chem.
272,
33125-33131 |
| 24. |
Gamble, M. V.,
Shang, E. Y.,
Zott, R. P.,
Mertz, J. R.,
Wolgemuth, D. J.,
and Blaner, W. S.
(1999)
J. Lipid Res.
40,
2279-2292 |
| 25. |
Yamamoto, H.,
Simon, A.,
Eriksson, U.,
Harris, E.,
Berson, E.,
and Dryja, T. P.
(1999)
Nat. Genet.
22,
188-191[CrossRef][Medline]
[Order article via Infotrieve] |
| 26. |
Driessen, C. A. G. G.,
Winkens, H. J.,
Hoffmann, K.,
Kuhlmann, L. D.,
Janssen, B. P. M.,
Van Vugt, A. H. M.,
Van Hooser, J. P.,
Wieringa, B. E.,
Deutman, A. F.,
Palczewski, K.,
Ruether, K.,
and Janssen, J. J. M.
(2000)
Mol. Cell. Biol.
20,
4275-4287 |
| 27. |
Deltour, L.,
Foglio, M. H.,
and Duester, G.
(1999)
Dev. Genet.
25,
1-10[CrossRef][Medline]
[Order article via Infotrieve] |
| 28. |
Deltour, L.,
Foglio, M. H.,
and Duester, G.
(1999)
J. Biol. Chem.
274,
16796-16801 |
| 29. |
Kamm, J. J.
(1982)
J. Am. Acad. Dermatol.
6,
652-659[Medline]
[Order article via Infotrieve] |
| 30. |
Biesalski, H. K.
(1989)
Toxicology
57,
117-161[CrossRef][Medline]
[Order article via Infotrieve] |
| 31. | Armstrong, R. B., Ashenfelter, K. O., Eckhoff, C., Levin, A. A., and Shapiro, S. S. (1994) in The Retinoids: Biology, Chemistry, and Medicine (Sporn, M. B. , Roberts, A. B. , and Goodman, D. S., eds), 2nd Ed. , pp. 545-572, Raven Press, Ltd., New York |
| 32. |
Nelson, M.
(1990)
Br. Med. J.
301,
1176 |
| 33. |
Mortensen, R. M.,
Zubiaur, M.,
Neer, E. J.,
and Seidman, J. G.
(1991)
Proc. Natl. Acad. Sci. U. S. A.
88,
7036-7040 |
| 34. | Joyner, A. L. (1993) Gene Targeting: a Practical Approach , IRL Press, Oxford |
| 35. | Hogan, B., Beddington, R., Costantini, F., and Lacy, E. (1994) Manipulating the Mouse Embryo , 2nd Ed. , Cold Spring Harbor Laboratory, Cold Spring Harbor |
| 36. |
Zhang, K.,
Bosron, W. F.,
and Edenberg, H. J.
(1987)
Gene
57,
27-36[CrossRef][Medline]
[Order article via Infotrieve] |
| 37. |
Haselbeck, R. J.,
and Duester, G.
(1997)
Alcohol. Clin. Exp. Res.
21,
1484-1490[CrossRef][Medline]
[Order article via Infotrieve] |
| 38. |
Collins, M. D.,
Eckhoff, C.,
Chahoud, I.,
Bochert, G.,
and Nau, H.
(1992)
Arch. Toxicol.
66,
652-659[CrossRef][Medline]
[Order article via Infotrieve] |
| 39. |
Litchfield, J. T., Jr.,
and Wilcoxon, F.
(1949)
J. Pharmacol. Exp. Ther.
96,
99-117 |
| 40. |
Haselbeck, R. J.,
Ang, H. L.,
and Duester, G.
(1997)
Dev. Dyn.
208,
447-453[CrossRef][Medline]
[Order article via Infotrieve] |
| 41. |
Algar, E. M.,
Seeley, T.-L.,
and Holmes, R. S.
(1983)
Eur. J. Biochem.
137,
139-147[Medline]
[Order article via Infotrieve] |
| 42. |
Roberts, E. S.,
Vaz, A. D. N.,
and Coon, M. J.
(1992)
Mol. Pharmacol.
41,
427-433[Abstract] |
| 43. |
Lieber, C. S.
(1994)
J. Toxicol. Clin. Toxicol.
32,
631-681[Medline]
[Order article via Infotrieve] |
| 44. |
Kono, H.,
Bradford, B. U.,
Yin, M.,
Sulik, K. K.,
Koop, D. R.,
Peters, J. M.,
Gonzalez, F. J.,
McDonald, T.,
Dikalova, A.,
Kadiiska, M. B.,
Mason, R. P.,
and Thurman, R. G.
(1999)
Am. J. Physiol.
277,
G1259-G1267 |
This article has been cited by other articles:
![]() |
M. Zaitseva, B. J. Vollenhoven, and P. A.W. Rogers Retinoic acid pathway genes show significantly altered expression in uterine fibroids when compared with normal myometrium Mol. Hum. Reprod., August 1, 2007; 13(8): 577 - 585. [Abstract] [Full Text] [PDF] |
||||
|
|